Stem Cell Transplant for Myelofibrosis

Myelofibrosis is a serious bone marrow disorder in which progressive scarring disrupts normal blood cell production,
leading to anemia, enlarged spleen, and significant fatigue. Among available interventions,
stem cell transplant for myelofibrosis remains the only treatment with the potential to achieve
long-term remission or cure, making it a central consideration in disease management for eligible patients.

Key Takeaways

• Allogeneic stem cell transplant is currently the only potentially curative treatment for myelofibrosis.
• Patient eligibility depends on disease risk score, overall health, age, and donor availability.
• Survival rates vary widely based on risk category and transplant-related complications, including graft-versus-host disease.
• The transplant process involves conditioning therapy, donor cell infusion, and a lengthy recovery and monitoring period.
• Careful pre-transplant evaluation and post-transplant follow-up are critical for optimizing outcomes.

How Stem Cell Transplant for Myelofibrosis Works

Allogeneic hematopoietic stem cell transplantation (HSCT) replaces a patient’s diseased bone marrow with healthy,
donor-derived stem cells capable of producing normal blood cells. In myelofibrosis, the bone marrow becomes
progressively replaced by fibrous tissue, impairing the generation of red blood cells, white blood cells, and
platelets. Transplanted donor stem cells engraft in the marrow cavity, restore healthy hematopoiesis, and can
reduce or eliminate fibrosis over time.

Before the transplant, patients receive a preparative or conditioning regimen consisting of high-dose chemotherapy,
radiation, or reduced-intensity combinations. This regimen serves two purposes: it suppresses the patient’s immune
system to prevent rejection of donor cells, and it reduces the tumor burden within the marrow. Reduced-intensity
conditioning (RIC) protocols have expanded transplant access to older or less fit patients who cannot tolerate
full-intensity regimens, without significantly compromising outcomes in carefully selected cases.

Once donor stem cells are infused, a process called engraftment begins, during which donor cells migrate to the
bone marrow and start producing healthy blood cells. Engraftment typically takes two to four weeks, though full
immune reconstitution can take months to years. The graft-versus-tumor effect, in which donor immune cells
recognize and attack residual diseased cells, contributes meaningfully to long-term disease control and is one of
the biological mechanisms that makes transplantation potentially curative.

Eligibility Criteria and Treatment Options for Bone Marrow Transplant

Not every patient with myelofibrosis qualifies for transplantation. Myelofibrosis stem cell transplant
eligibility criteria are based on a combination of disease-related and patient-related factors assessed
through structured clinical evaluation. Physicians rely on validated prognostic scoring systems — most commonly
the Dynamic International Prognostic Scoring System (DIPSS) — to classify patients as low, intermediate-1,
intermediate-2, or high risk. Transplant is generally recommended for patients in the intermediate-2 or high-risk
categories, where the disease burden justifies the procedure’s inherent risks.

Patient-related factors include age, performance status, organ function, and the presence of comorbidities such
as heart, liver, or kidney disease. While there is no strict upper age cutoff, most transplant centers evaluate
patients up to approximately 70–75 years old on an individual basis, particularly when RIC regimens are used.
Donor availability is equally important; a matched sibling donor offers the best outcomes, though matched unrelated
donors and haploidentical (half-matched) donors are viable alternatives when a sibling match is unavailable.

Bone marrow transplant myelofibrosis treatment options also include pre-transplant therapies
designed to optimize a patient’s condition before proceeding. JAK inhibitors such as ruxolitinib are frequently
used prior to transplant to reduce spleen size, improve constitutional symptoms, and enhance the patient’s overall
fitness. While ruxolitinib does not cure myelofibrosis, it can make transplant safer and better tolerated by
stabilizing disease activity in the weeks leading up to the procedure. The decision to transplant is always made
collaboratively between the patient and a multidisciplinary specialist team.

Risks, Side Effects, and Survival Rates of Stem Cell Transplant for Myelofibrosis

Transplantation carries substantial risks that must be weighed carefully against the potential for cure. The most
significant complication is graft-versus-host disease (GVHD), a condition in which donor immune cells attack the
recipient’s healthy tissues. Acute GVHD typically develops within the first 100 days after transplant and can
affect the skin, gastrointestinal tract, and liver. Chronic GVHD may emerge later and can be long-lasting,
affecting quality of life considerably. Preventive immunosuppressive therapy is used routinely, though it
introduces its own risks, including increased susceptibility to infection.

The risks and side effects of stem cell transplant for myelofibrosis extend beyond GVHD. Patients
may experience severe infections during the period of immune suppression, bleeding due to low platelet counts,
organ toxicity from the conditioning regimen, and graft failure — a serious complication in which donor cells
do not establish themselves successfully in the marrow. Transplant-related mortality (TRM), which refers to
death caused by the procedure rather than the underlying disease, remains a meaningful concern and varies
depending on patient fitness, donor match quality, and center experience.

Regarding the stem cell transplant survival rate for myelofibrosis, outcomes differ considerably
by risk group and transplant center. Published studies report five-year overall survival rates broadly ranging from
approximately 30% to 60%, with better outcomes observed in younger patients, those with lower disease risk scores,
and those receiving a well-matched donor graft. Relapse after transplant occurs in a subset of patients, and
management may include donor lymphocyte infusions (DLI) to reinforce the graft-versus-tumor effect. Ongoing
advances in conditioning regimens, GVHD prevention, and supportive care continue to improve these figures.

What to Expect During and After the Transplant Process

The transplant journey begins weeks before the actual infusion. Patients undergo a thorough pre-transplant
evaluation that includes imaging, cardiac and pulmonary function tests, blood work, and psychological assessment.
Once cleared, they are admitted to a specialized transplant unit and begin the conditioning regimen, which
typically lasts four to seven days. During this phase, patients often experience fatigue, nausea, mucositis
(painful mouth sores), and a sharp decline in blood counts as the existing marrow is suppressed.

The stem cell infusion itself — often called “day zero” — is administered intravenously and resembles a blood
transfusion in appearance. The critical period that follows involves close monitoring for engraftment, infection,
and early signs of GVHD. Most patients remain hospitalized for three to six weeks, depending on their recovery
trajectory. Blood transfusions and platelet support are commonly needed during this window to manage low counts
while the new marrow establishes itself.

After discharge, outpatient monitoring continues intensively for at least the first year. Patients attend
frequent clinic visits for blood tests, medication adjustments, and assessment of GVHD symptoms. Immunosuppressive
medications are gradually tapered as immune reconstitution progresses. Full recovery, including return to normal
activity levels and immune function, can take one to two years or longer. Emotional support, nutritional guidance,
and rehabilitation services are integral to comprehensive post-transplant care and significantly influence
long-term quality of life.

Understanding what lies ahead empowers patients to prepare meaningfully. Key practical considerations during
recovery include:

• Avoiding crowded public spaces during periods of immune suppression to reduce infection risk
• Following dietary restrictions to minimize exposure to foodborne pathogens
• Adhering strictly to immunosuppressive medication schedules as prescribed
• Reporting new or worsening symptoms — such as skin changes, diarrhea, or jaundice — promptly to the care team
• Attending all scheduled follow-up appointments, including bone marrow biopsies to assess engraftment and disease response

Frequently Asked Questions

Is stem cell transplant the only cure for myelofibrosis?

Currently, allogeneic stem cell transplantation is the only treatment shown to potentially cure myelofibrosis
by replacing the diseased marrow with healthy donor cells. Other therapies, including JAK inhibitors like
ruxolitinib, effectively manage symptoms and slow progression but do not eliminate the underlying disease.
Transplant is typically reserved for intermediate-2 and high-risk patients where the potential benefit outweighs
the substantial procedural risks.

Can older patients receive a stem cell transplant for myelofibrosis?

Age alone does not disqualify a patient from transplantation. Reduced-intensity conditioning regimens have made
transplant feasible for appropriately selected patients up to approximately 70–75 years of age. Eligibility is
determined by overall health, organ function, and performance status rather than chronological age. Each case
is evaluated individually by a multidisciplinary transplant team to determine whether the procedure is safe
and appropriate.

When does disease relapse occur after transplant, and how is it managed?

Relapse can occur months to years post-transplant and is more common in high-risk patients or those with
incomplete donor chimerism. Management options include tapering immunosuppression to enhance the graft-versus-tumor
effect, donor lymphocyte infusions (DLI), or, in some cases, a second transplant. JAK inhibitors may also be
used post-relapse to control symptoms. Early detection through regular bone marrow assessments improves the
likelihood of a successful response to salvage strategies.